Fertility

 
 ANTARCTICA 2
 
 SCRaTCH OFO
 ALIFE2
 
 exIUI
 
 FOAM
 
 IVF 38+
 Medium II
 
 SCRaTCH
 
 SelecTIMO
 STIM
 > T4-LIFE
 TRUST
 
 ZinenZwanger
 PRORAILS
 ALIFE
 Bedrust
 ESEP
 H2Olie
 Freeze-all (progesterone)
 IMPROvEMENT
 INeS
 inSIGHT
 Lifestyle
 MASTER
 M-ovin"
 OPTIMIST
 Promise
 SUPER

 AID-study
 Antarctica study
 Congeno study
 DESH trial
 ENDO-RECEPT
 Follikel diameter
 IVM study
 L-Age
 Medium
 Metex
 Pr_OVIN
 PRIMA
 SETI
 THL
 

T4-LIFE

Go to the T4-LIFE website.


Objective
To assess improvement in live birth rate and pregnancy outcome after levothyroxine supplementation in women with recurrent miscarriage and thyroid autoimmunity.

Study design
Randomised double blind placebo controlled multi centre clinical trial.

Study population
Women with recurrent miscarriage, i.e. at least 2 miscarriages, aged 18-42 years. Women will be recruited in the Netherlands (Coordinating Centre Academic Medical Centre, Amsterdam) and internationally.

Intervention
The intervention group receives levothyroxine, and the control group receives placebo of identical appearance.

Outcome measures
Primary outcome measure: live birth rate.
Secondary outcome measures: miscarriage rate, preterm birth, any maternal or neonatal adverse pregnancy outcomes.

Power/data analysis
We expect an increase in live birth rate from 55% to 75% (intention to treat population). This is based on a live birth rate from 55% in case of recurrent miscarriage and untreated thyroid autoimmunity14. A high relative risk reduction of 52% for miscarriages was shown in a recent meta analysis for women with thyroid autoimmunity treated with levothyroxine 20.
To detect a Minimally Important Difference (MID) of 20% in live birth beyond 24 weeks (from 55% to 75 %), with an alpha error rate of 5% and beta error rate of 20% (i.e. 80% power), 90 women will need to be randomised to the intervention arm, and 90 women to the control arm (180 in total. Assuming and adjusting for a worst case scenario of a loss to follow-up rate of 5%, the total number of participants required will be 200 (100 in each arm of the trial). We expect 15% in each group will have to be excluded after randomisation because of development of (sub) clinical hypothyroidism. To make sure we can account for these drop-outs we will allocate 120 patients to each group.

Projectleaders
Dr. M. Goddijn, Academic Medical Centre
Dr. P.H. Bisschop, Academic Medical Centre
Prof.dr. E. Fliers, Academic Medical Centre
Prof. dr. J.A.M. van der Post, Academic Medical Centre
Prof. dr. B.W. Mol, Academic Medical Centre
Dr. Kuchenbecker, Isala Kliniek
Dr. H.R. Verhoeve, Onze Lieve Vrouwe Gasthuis
Dr. K.W.M. Bloemenkamp, Leids Universitair Medisch Centrum


Methodology
Dr. M. van Wely, Epidemiologist, Academic Medical Centre

Subsidy
Fonds Nuths Ohra
Jan Dekkerstichting en dr Ludgardine Bouwmanstichting

Contact (researcher)
Drs. M. van Dijk, PhD student, Academic Medical Centre
Meibergdreef 9, Location H4-240
1105 AZ Amsterdam
m.m.vandijk@amc.nl